Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
Open Access
- 30 March 2020
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 11 (6) , 1746-1751
Abstract
Immune checkpoint inhibitors (ICIs) are nowadays widely used in clinical oncology treatment, and significantly improve the prognosis of cancer patients. However, overactivation of T cells and related signaling pathways caused by ICIs can also induce immune‐related adverse effects (irAEs). Renal immune side‐effects are relatively rare, but some are serious and fatal. Acute kidney injury (AKI), diagnosed mainly by percentage increases in serum creatinine (sCr), is the most common clinical manifestation, while acute tubulointerstitial nephritis (ATIN) is the main cause of ICI‐related AKI. Urinalysis analysis and sediment evaluation, 24 hour urine protein and sCr are helpful in screening and monitoring renal irAEs. Multiple potential causes for AKI are involved during cancer therapy, and should be differentiated from the immune mechanisms of ICIs. Under these circumstances, a renal biopsy should be considered which is essential for clinical decision‐making. Steroids are an effective treatment option for renal irAEs. Most patients who experience ICI‐related ATIN achieve a partial or complete renal recovery with prompt diagnosis and treatment. Multidisciplinary collaborations of different specialists will improve the effectiveness and outcome in the management of ICI irAEs.Keywords
Funding Information
- Chinese Academy of Medical Science (CAMS) Initiative for Innovative Medicine (2016-I2M-1-002, 2017-I2M-2-001)
This publication has 20 references indexed in Scilit:
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative ReviewAmerican Journal of Nephrology, 2017
- Renal effects of immune checkpoint inhibitorsNephrology Dialysis Transplantation, 2016
- Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted TherapiesAdvances in Anatomic Pathology, 2016
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanomaClinical Kidney Journal, 2016
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treatment Reviews, 2016
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapyMedical Oncology, 2010
- Anti-CTLA4 Antibody–Induced Lupus NephritisNew England Journal of Medicine, 2009
- PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesisClinical Immunology, 2005